1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Internal deadline was June 7, 2018; official submission deadline was June 14, 2018. The call is explicitly marked closed.
Innovative Medicines Initiative 2 (IMI2) Joint Undertaking - Call 14: Topic 4 is a grant from the IMI2 Joint Undertaking, a public-private partnership between the European Commission and EFPIA, that funds the establishment of a Centre of Excellence for remote decentralised clinical trials (DCT). This initiative supports Research and Innovation Actions with EU funding matched by pharmaceutical industry contributions.
The scope covers developing infrastructure and methodologies for conducting clinical trials remotely and at scale across Europe. Eligible applicants are typically consortia of academic institutions, healthcare organizations, and industry partners.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Innovative Medicine Initiative 2 – Call 14 The Innovative Medicines Initiative 2 (IMI2) Joint Undertaking is a public-private partnershipbetween the European Commission and EFPIA (the European Federation of PharmaceuticalIndustry and Associations), implemented through public-private consortia to carry out research orother actions, where the EU provides funding and EFPIA and other members matching the EUfunding with their own contributions.
IMI2 supports the development and implementation of precompetitiveresearch and innovation actions and any relevant accompanying measures to improveEuropean citizens' health and well-being. The present call will fund one Research and Innovation Action in each of the following topics: Topic 1: Targeted immune intervention for the management of non-response and relapse.
Scope:identify new approaches to: a) characterise human immune-mediated diseases; b) profile andanalyse immune cells obtained from non-blood tissues; c) discover individual disease and crossdiseasebiomarkers predictive of treatment response, non-response, relapse and flare-up; d) performearly phase clinical trials (e.g. enriched study populations for certain molecular pathways; adaptiveand basket trial designs etc.) and identify potential novel patient-centric treatment approaches.
The focus will be on patients from well-characterised immune-mediated diseases. The ultimate goal is todevelop a translational research platform that will improve patient management and personalisedtreatment by identification/validation of predictive biomarkers for non-response, rapid progressionand remission. Grant: 40,1 million euro.
Topic 2: Non-invasive clinical molecular imaging of immune cells. Scope: to establish a consortiumthat can develop and validate a quantitative, non-invasive, immune cell imaging platform, whichincludes novel and target-specific molecular imaging agents, (hybrid) imaging modalities, andimage processing algorithms.
The topic aims to validate immune cell targets based on humanbiology and to facilitate precision medicine by identification and stratification of patients andprediction of therapeutic outcomes. Topic 3: Development of a platform for federated and privacy-preserving machine learning insupport of drug discovery.
Scope: delivery of a federated and privacy-preserving machine learningplatform, initially validated on publicly accessible data, that is demonstrably safe enough andscalable enough to be deployed to a significant representation of private data in the actualpreclinical data warehouses of the participating major pharmaceutical companies in yearlyevaluation runs. Topic 4: Centre of excellence – remote decentralised clinical trials (DCT).
Scope: to disaggregatethe current model of running clinical trials, defining building blocks and mapping new technologies(e.g. telemedicine, mobile health…) to support the new DCT model. The objective is to demonstratethe feasibility of running remote DCTs in Europe.
This will increase access of patients to clinicalresearch, enriching clinical trial data from a more diverse and representative patient population andimprove patient experience during the trials, with a higher speed of recruitment and better retention.
Legal entities established in a Member State or Country associated to Horizon 2020 that fall withinone of the following categories: a) micro, small and medium-sized enterprises and other companieswith an annual turnover of EUR 500 million or less, the latter not being affiliated entities ofcompanies with an annual turnover of more than 500 million; b) secondary and higher educationestablishments; c) non-profit organisations, including those carrying out research or technologicaldevelopment as one of their main objectives or those that are patient organisations.
The consortium must include at least three legal entities established in 3 EU Member States orHorizon 2020 associated countries. Coverage of 100% of the project costs. http://www.
imi. europa. eu/apply-funding/open-calls/imi2-call-14 I'm interested in this call
According to the current listing, eligibility includes: Legal entities established in a Member State or Country associated to Horizon 2020. Confirm the full requirements in the official notice before applying.
The current listing shows 19 million euros (Topic 4). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Innovative Medicines Initiative 2 (IMI2) Joint Undertaking - Call 14: Topic 4: Centre of excellence – remote decentralised clinical trials (DCT) is funded by Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU). Verify program details on the funder's official page before applying.
This listing is flagged as international in scope. Check the official notice for country-specific restrictions before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
EPA's Innovative Water Infrastructure Workforce Development competition closes October 5, 2026. The agency says up to 15 awards across four project areas, but Project Area 1 alone carries a $7.8 million ceiling against a $10.8 million pot. That tension is the single most important strategic fact in the NOFO — here is how to read it, which lane is least competed, and what a three-week runway means for your submission.
Read articleThe FY2026 Innovative Water Infrastructure Workforce Development Grant (EPA-OW-OWM-26-03) closes October 5, 2026 with $10.8 million, up to 15 cooperative agreements, and a Project Area 1 ceiling of $7.8 million. One maximum award would consume 72 percent of the pool. Here is how the four project areas actually partition the money, why the grants.gov award floor field is wrong, and why September 14 is the date that matters more than October 5.
Read articleThe Innovative Postsecondary Models Fund — Gates, Lumina, Strada, Ascendium, ECMC, College Futures, Haas Jr., and Raikes, administered by Panorama Global — will make 7 to 10 grants of $750,000 to $1,000,000. Eligibility is unusually wide and the gates are unusually specific. One of them eliminates most applicants outright, and it has nothing to do with the quality of the idea.
Read article